Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients APIs , biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism.
The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Major Drugs. Contact Info. Lichtstrasse Executive Leadership. Joerg Reinhardt. Independent Non-Executive Chairman of the Board. Vasant Narasimhan. Enrico Vanni. Harry Kirsch. Steven Baert. New Stories.
Novartis has raised the prospect of divesting its generic drugs unit Sandoz after years of revamping the business, as price pressures mount in the off-patent drug sector. Novartis said on Monday its canakinumab drug had failed in another trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.
Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss. Novartis has halted a clinical trial of CFZ iscalimab in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday.
Novartis AG said on Wednesday it had agreed a deal with Britain's healthcare service provider for use of the drugmaker's new anti-cholesterol drug Leqvio, after the country's healthcare cost agency NICE approved the medicine. This is beginning with regulatory approvals obtained from January and after the relevant studies have been published. Request for pre trials will be reviewed on a case by case basis. They are fundamental to the development of innovative medicines or devices that treat and prevent illness Novartis publically shares clinical trial summary results for medicines under development and approved by regulatory agencies on the Novartis clinical trial results public website Novartis is committed to sharing with qualified external researchers, anonymized voluntary data and clinical study reports from our clinical trials for medicines in indications approved by regulators in the United State US and European Union EU Clinical trial results.
Ongoing trials. Voluntary data sharing. Request a free trial Log in. Novartis Overview Update this profile. Founded Status Public. Employees , Investments Ownership Status. Publicly Held. Financing Status. Primary Industry. Other Industries. Drug Discovery. Stock Exchange. Primary Office. What you see here scratches the surface Request a free trial. Want to dig into this profile? Novartis Stock Performance.
Novartis Financials Summary. Public Fundamental Data provided by Morningstar, Inc. Request a free trial. Novartis Comparisons. HQ Location. Total Raised. Post Valuation. Last Financing Details.
0コメント